In the setting of the COVID-19 pandemic, progression-free survival with first-line ibrutinib + venetoclax + obinutuzumab treatment was not superior to ibrutinib + obinutuzumab for older patients with previously untreated CLL. Follow-up remains ongoing, and many patients in the ibrutinib + venetoclax + obinutuzumab arm achieved undetectable measurable residual disease.
More research is presented again, proving that targeted therapies, in this case, ibrutinib, are significantly superior to chemoimmunotherapy (CIT) in front-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL).
This real-world study found that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib were more likely to need to change therapies or add an additional therapy compared with patients treated with ibrutinib.
Patients with acalabrutinib had lower discontinuation rates and a prolonged time to discontinuation compared to pts treated with ibrutinib.
The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)
I am grateful to Nathan Vardi for illuminating this incredible story’s corners, and I highly recommend his book.
These results offer some encouraging news regarding cancer care for adults with predominantly African ancestry
Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
